返回期刊详情
T
The Lancet Oncology
IF
论文数340
被引数1
期刊论文 340
发表时间
Single, early intravesical instillation of pirarubicin in the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403): a multicentre, open-label, randomised, phase 3 trial单次早期膀胱灌注吡柔比星预防上尿路尿路上皮癌根治性肾输尿管切除术后的膀胱复发(JCOG1403):一项多中心、开放标签、随机、III期临床试验
Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis系统治疗、胃切除术、肿瘤细胞减灭术和温热腹腔内化疗与单独系统治疗对比用于伴有局限性腹膜转移的胃癌(PERISCOPE II):一项多中心、随机对照、III期试验在计划外委托中期分析后的最终结果
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial曲妥珠单抗雷泽贝单抗与吡罗替尼联合卡培他滨用于HER2阳性转移性乳腺癌患者的比较(地平线-Breast01研究):一项多中心、开放标签、随机对照、III期试验的期中分析
SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trialSBRT联合阿比特龙醋酸盐和ADT与阿比特龙醋酸盐和ADT在寡转移性去势抵抗性前列腺癌中的比较(ARTO):一项开放标签、随机、II期试验的长期能预计划总体生存分析

